NICE verdict on Temozolomide: where next?
2002
NICE verdict on Temozolomide: where next?
Editorial
Evidence: low
Author Information
Author(s): Brada M
Primary Institution: The Institute of Cancer Research and The Royal Marsden NHS Trust
Conclusion
Temozolomide shows limited efficacy in treating recurrent malignant gliomas, particularly glioblastoma multiforme.
Supporting Evidence
- Temozolomide was developed in a UK laboratory and showed initial promise in treating malignant gliomas.
- Subsequent studies did not replicate the initial positive results, leading to questions about its effectiveness.
- The systematic review concluded that the evidence for Temozolomide's use in malignant glioma is weak.
Takeaway
Temozolomide is a new cancer drug that works a little but not as well as hoped for some brain tumors.
Potential Biases
Potential commercial interests may influence the assessment of Temozolomide.
Limitations
The evidence base for Temozolomide's effectiveness is weak, and many clinical trials have failed to find effective treatment strategies.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website